617 related articles for article (PubMed ID: 34413211)
1. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
[TBL] [Abstract][Full Text] [Related]
2. Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19.
Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Frum T; Kadambi NS; Amin AT; O'Meara TR; Pretto CD; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Sexton JZ
bioRxiv; 2020 Dec; ():. PubMed ID: 32577649
[TBL] [Abstract][Full Text] [Related]
3. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.
Bakowski MA; Beutler N; Wolff KC; Kirkpatrick MG; Chen E; Nguyen TH; Riva L; Shaabani N; Parren M; Ricketts J; Gupta AK; Pan K; Kuo P; Fuller M; Garcia E; Teijaro JR; Yang L; Sahoo D; Chi V; Huang E; Vargas N; Roberts AJ; Das S; Ghosh P; Woods AK; Joseph SB; Hull MV; Schultz PG; Burton DR; Chatterjee AK; McNamara CW; Rogers TF
Nat Commun; 2021 Jun; 12(1):3309. PubMed ID: 34083527
[TBL] [Abstract][Full Text] [Related]
4. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
5. Kite-Shaped Molecules Block SARS-CoV-2 Cell Entry at a Post-Attachment Step.
Chan SW; Shafi T; Ford RC
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835112
[TBL] [Abstract][Full Text] [Related]
6. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
[TBL] [Abstract][Full Text] [Related]
7. Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches.
Watashi K
Biochem Biophys Res Commun; 2021 Jan; 538():137-144. PubMed ID: 33272566
[TBL] [Abstract][Full Text] [Related]
8. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro.
Raymonda MH; Ciesla JH; Monaghan M; Leach J; Asantewaa G; Smorodintsev-Schiller LA; Lutz MM; Schafer XL; Takimoto T; Dewhurst S; Munger J; Harris IS
Virology; 2022 Jan; 566():60-68. PubMed ID: 34871905
[TBL] [Abstract][Full Text] [Related]
10. Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19.
Cao J; Liu Y; Zhou M; Dong S; Hou Y; Jia X; Lan X; Zhang Y; Guo J; Xiao G; Wang W
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215943
[TBL] [Abstract][Full Text] [Related]
11. High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.
Choi R; Zhou M; Shek R; Wilson JW; Tillery L; Craig JK; Salukhe IA; Hickson SE; Kumar N; James RM; Buchko GW; Wu R; Huff S; Nguyen TT; Hurst BL; Cherry S; Barrett LK; Hyde JL; Van Voorhis WC
PLoS One; 2021; 16(4):e0250019. PubMed ID: 33886614
[TBL] [Abstract][Full Text] [Related]
12. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses.
Schreiber A; Viemann D; Schöning J; Schloer S; Mecate Zambrano A; Brunotte L; Faist A; Schöfbänker M; Hrincius E; Hoffmann H; Hoffmann M; Pöhlmann S; Rescher U; Planz O; Ludwig S
Cell Mol Life Sci; 2022 Jan; 79(1):65. PubMed ID: 35013790
[TBL] [Abstract][Full Text] [Related]
13. Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro.
Morokutti-Kurz M; Fröba M; Graf P; Große M; Grassauer A; Auth J; Schubert U; Prieschl-Grassauer E
PLoS One; 2021; 16(2):e0237480. PubMed ID: 33596218
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.
Plaze M; Attali D; Prot M; Petit AC; Blatzer M; Vinckier F; Levillayer L; Chiaravalli J; Perin-Dureau F; Cachia A; Friedlander G; Chrétien F; Simon-Loriere E; Gaillard R
Int J Antimicrob Agents; 2021 Mar; 57(3):106274. PubMed ID: 33387629
[TBL] [Abstract][Full Text] [Related]
15. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
[TBL] [Abstract][Full Text] [Related]
16. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2
Good SS; Westover J; Jung KH; Zhou XJ; Moussa A; La Colla P; Collu G; Canard B; Sommadossi JP
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558299
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of itraconazole against SARS-CoV-2.
Van Damme E; De Meyer S; Bojkova D; Ciesek S; Cinatl J; De Jonghe S; Jochmans D; Leyssen P; Buyck C; Neyts J; Van Loock M
J Med Virol; 2021 Jul; 93(7):4454-4460. PubMed ID: 33666253
[TBL] [Abstract][Full Text] [Related]
18. Protective Effects of Lactoferrin against SARS-CoV-2 Infection In Vitro.
Salaris C; Scarpa M; Elli M; Bertolini A; Guglielmetti S; Pregliasco F; Blandizzi C; Brun P; Castagliuolo I
Nutrients; 2021 Jan; 13(2):. PubMed ID: 33498631
[TBL] [Abstract][Full Text] [Related]
19. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
Aherfi S; Pradines B; Devaux C; Honore S; Colson P; Scola B; Raoult D
Future Microbiol; 2021 Nov; 16():1341-1370. PubMed ID: 34755538
[TBL] [Abstract][Full Text] [Related]
20. Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing.
Glebov OO
FEBS J; 2020 Sep; 287(17):3664-3671. PubMed ID: 32428379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
